Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Main Article Content

A Blauvelt
RB Warren
K Reich
et al.



Abstract not available.


Disclosures: Study sponsored by UCB.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>